

**Table S1. Selectivity of RNAP-inhibitory activity (related to Fig. 1B)**

enzyme	IC50 ( $\mu\text{M}$ ) ( $\pm$ SEM)	selectivity ratio
<b>promoter-dependent transcription</b>		
<b><i>E. coli</i> RNAP</b>		
6.25 $\mu\text{M}$ UTP	0.1	[1]
50 $\mu\text{M}$ UTP	2	[1]
250 $\mu\text{M}$ UTP	8	[1]
<b>human RNAP I</b>		
6.25 $\mu\text{M}$ UTP	>50	>500
50 $\mu\text{M}$ UTP	ND	ND
250 $\mu\text{M}$ UTP	ND	ND
<b>human RNAP II</b>		
6.25 $\mu\text{M}$ UTP	1	10
50 $\mu\text{M}$ UTP	7	4
250 $\mu\text{M}$ UTP	>20	>3
<b>human RNAP III</b>		
6.25 $\mu\text{M}$ UTP	9	90
50 $\mu\text{M}$ UTP	ND	ND
250 $\mu\text{M}$ UTP	ND	ND
<b>promoter-independent transcription</b>		
<b><i>E. coli</i> RNAP</b>		
1.56 $\mu\text{M}$ UTP	0.9 ( $\pm$ 0.1)	[1]
25 $\mu\text{M}$ UTP	4 ( $\pm$ 0.7)	[1]
400 $\mu\text{M}$ UTP	10 ( $\pm$ 2)	[1]
<b>HeLa nuclear extract (human RNAP I / II / III)</b>		
1.56 $\mu\text{M}$ UTP	4 ( $\pm$ 0.1)	4
25 $\mu\text{M}$ UTP	15 ( $\pm$ 6)	4
400 $\mu\text{M}$ UTP	51 ( $\pm$ 30)	5

**Table S2. Antibacterial activity *in vivo* (mouse *S. pyogenes* peritonitis model; 7 day survival) (related to Fig. 1D)**

intravenous (iv) administration, 10 min and 6 h post-infection		intravenous (iv) administration, 10 min post-infection		subcutaneous (sc) administration, 10 min post-infection	
PUM total dose (mg/kg)	survivors / total	PUM total dose (mg/kg)	survivors / total	PUM total dose (mg/kg)	survivors / total
50	7 / 8	40	5 / 8	40	6 / 8
20	6 / 8	16	4 / 8	16	2 / 8
8	5 / 8	6.4	0 / 8	6.4	1 / 8
3.2	0 / 8	2.56	2 / 8	2.56	1 / 8
0	0 / 8	1.024	0 / 8	1.024	0 / 8
		0	0 / 8	0	0 / 8

**Table S3. Data collection and refinement statistics (related to Fig. 4)**

	<b>RPo-GpA-PUM</b>	<b>RPo-GpA-CMPcPP</b>
	<b>(PDB: 5X21)</b>	<b>(PDB: 5X22)</b>
<b>data collection</b>		
space group	C2	P2 <sub>1</sub>
cell dimensions		
<i>a, b, c</i> (Å)	186.8, 103.1, 296.2	186.4, 104.3, 297.3
$\alpha, \beta, \gamma$ (°)	90.0, 98.7, 90.0	90.0, 98.4, 90.0
resolution (Å)	40.00-3.30 (3.36-3.30)*	50.00-3.35 (3.41-3.35)*
<i>R</i> <sub>syn</sub> or <i>R</i> <sub>merge</sub>	0.138 (0.633)	0.197 (>1.0)
<i>I</i> / $\sigma$ ( <i>I</i> )	8.4 (1.7)	7.7 (1.8)
completeness (%)	0.920 (0.874)	0.956 (0.891)
redundancy	3.4 (3.4)	5.3 (5.3)
<b>refinement</b>		
resolution (Å)	50.00-3.32	50.00-3.33
number of reflections	70085	147976
<i>R</i> <sub>work</sub> / <i>R</i> <sub>free</sub>	0.232/0.280	0.208/0.250
number of atoms		
protein/DNA/RNA	28662	56787
ligand/ion	42	76
water	35	0
<i>B</i> factors		
protein	61.6	41.8
ligand/ion	31.8	21.0
Water	34.3	-
r.m.s deviations		
bond lengths (Å)	0.002	0.007
bond angles (°)	0.542	0.834

\*Values in parentheses are for highest-resolution shell.

**Table S4. Oligonucleotides (related to STAR Methods section)**

name	sequence
<i>recA</i> promoter DNA fragment 1	5'-GGCGACCGTGATGCGGTGCGTCGTCAGGCTACTGCGTATGCATTGCAGACCTTGTGGCAAC AATTTCTACAAAACACTTGATACTGTATGAGCATAACAGTATAAATTGCTTCAGATCTCTAGAAGCT TTAATGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGGCACCGTGTATGAAATCTAAC AATGCGCTCATCGTCATCCTCGGCACCGTCACCCTGGATGCTCTAGGCATAGGCTTGGTTATG CCGGTACTGCCGGCCTCTTGCGGGATATCGTCCATTCCGACAGCATCGCCAGTCACTATGG CGTGTCTAGCGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTC CGACCGCTTTGGCCGCCGCCAGTCTGCTCGCTTCGCTACTTGGAGCCACTATCGACTACG CGATCATGGCGACCACACCCGTCCTGT-3'
<i>recA</i> promoter DNA fragment 2	5'-GGCGACCGTGATGCGGTGCGTCGTCAGGCTACTGCGTATGCATTGCAGACCTTGTGGCAAC AATTTCTACAAAACACTTGATACTGTATGAGCATAACAGTATAAATTGCTTCAGATCTCTAGAAGCT AAGTTAGTTCGTTACGCGACACGCGGCAACAAG-3'
<i>recA</i> promoter DNA fragment 3	5'-GGCGACCGTGATGCGGTGCGTCGTCAGGCTACTGCGTATGCATTGCAGACCTTGTGGCAAC AATTTCTACAAAACACTTGATACTGTATGAGCATAACAGTATAAATTGCTTCAGATCTCTAGAAGCT AAGGAGACCAACGCAGCGACACGCGGCAACAAG-3'
bacteriophage T4 N25 promoter DNA fragment	5'-TTGCTTTTCAGGAAAATTTTTCTGTATAATAGATTCATAAATTTGAGAGAGGAGTTTAAATATGG CTGGTTCTCGCGAGAATTCCGAATAGCCATCCCAATCGAACAGGCCTGCTGGTAATCGCAGGC TTTTTATTT-3'
Cy5-labelled <i>lacUV5</i> promoter DNA fragment	5'-Cy5-AGGCTTTACACTTTATGCTTCCGGCTCGTATAATGTGTGGAATTGTGAGCGGATA-3'
<i>S. pyogenes rpoB</i> forward primer	5'-GGGCAAATGATAACTTAGTTGCGATTGCTG-3'
<i>S. pyogenes rpoB</i> reverse primer	5'-CCTTTCTGCCTTTGATGACTTTACCAGTTC-3'
<i>S. pyogenes rpoC</i> forward primer	5'-GCTCAAGAACTCAAGAAGTTTCTGAAACAACTGAC-3'
<i>S. pyogenes rpoC</i> reverse primer	5'-GTCAATGCTTTTTACTGCCAACAACTCAGAC-3'

**Table S5. Nucleic-acid scaffolds for single-nucleotide-addition reactions (related to STAR Methods section)**

incoming NTP	RNA 3' end	nucleic-acid scaffold <sup>1</sup>
UTP	G	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGCATGCGGTCTGTCCC - 5' 5' - *CGGCGCGCG - 3'
GTP	G	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGCCTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCG - 3'
ATP	G	5' - tCGCCAGACAGGG - 3' 3' - GCCGCGCGCTaGCGGTCTGTCCC - 5' 5' - *CGGCGCGCG - 3'
CTP	G	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGCGTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCG - 3'
UTP	A	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGTATGCGGTCTGTCCC - 5' 5' - *CGGCGCGCA - 3'
GTP	A	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGTCTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCA - 3'
ATP	A	5' - tCGCCAGACAGGG - 3' 3' - GCCGCGCGTTaGCGGTCTGTCCC - 5' 5' - *CGGCGCGCA - 3'
CTP	A	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCA - 3'
UTP	U	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGAATGCGGTCTGTCCC - 5' 5' - *CGGCGCGCU - 3'
GTP	U	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGACTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCU - 3'
ATP	U	5' - tCGCCAGACAGGG - 3' 3' - GCCGCGCGATaGCGGTCTGTCCC - 5' 5' - *CGGCGCGCU - 3'
CTP	U	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGAGTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCU - 3'
UTP	C	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGGATGCGGTCTGTCCC - 5' 5' - *CGGCGCGCC - 3'
GTP	C	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGGCTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCC - 3'
ATP	C	5' - tCGCCAGACAGGG - 3' 3' - GCCGCGCGGTaGCGGTCTGTCCC - 5' 5' - *CGGCGCGCC - 3'
CTP	C	5' - ACGCCAGACAGGG - 3' 3' - GCCGCGCGGGTGCGGTCTGTCCC - 5' 5' - *CGGCGCGCC - 3'

<sup>1</sup>black, DNA; red, RNA, asterisk, <sup>32</sup>P.